Spero Therapeutics Inc (NAS:SPRO)

$ 1.03 0.0861 (9.12%) Market Cap: 56.15 Mil Enterprise Value: -20.21 Mil PE Ratio: 12.88 PB Ratio: 0.85 GF Score: 39/100

Q2 2024 Spero Therapeutics Inc Earnings Call Transcript
Aug 05, 2024

$1.34 (+2.29%)

Earnings
Q4 2023 Spero Therapeutics Inc Earnings Call Transcript
Mar 13, 2024

$1.66

Earnings
Q3 2023 Spero Therapeutics Inc Earnings Call Transcript
Nov 13, 2023

$1.11

Earnings
Spero Therapeutics Inc Annual Shareholders Meeting Transcript
Oct 05, 2023
Spero Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Q2 2023 Spero Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

$1.45

Earnings
Q1 2023 Spero Therapeutics Inc Earnings Call Transcript
May 11, 2023

$1.92 (+1.05%)

Earnings
Spero Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Q4 2022 Spero Therapeutics Inc Earnings Call Transcript
Mar 30, 2023

$1.44 (-0.69%)

Earnings
Spero Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Q3 2022 Spero Therapeutics Inc Earnings Call Transcript
Nov 14, 2022

$2.03 (+1.50%)

Earnings
Spero Therapeutics Inc R&D Event Transcript
Oct 06, 2022
Q2 2022 Spero Therapeutics Inc Earnings Call Transcript
Aug 10, 2022

$0.85 (+9.51%)

Earnings
Q1 2022 Spero Therapeutics Inc Earnings Call Transcript
May 16, 2022

$1.71

Earnings
Spero Therapeutics Inc Conference Call Transcript
May 03, 2022
Q4 2021 Spero Therapeutics Inc Earnings Call Transcript
Mar 31, 2022

$8.7 (+1.05%)

Earnings
Q3 2021 Spero Therapeutics Inc Earnings Call Transcript
Nov 10, 2021

$17.02 (-1.39%)

Earnings
Q2 2021 Spero Therapeutics Inc Earnings Call Transcript
Aug 05, 2021

$14.18 (+3.73%)

Earnings
Spero Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 13, 2021
Q1 2021 Spero Therapeutics Inc Earnings Call Transcript
May 06, 2021

$12.75 (-0.47%)

Earnings
Q4 2020 Spero Therapeutics Inc Earnings Call Transcript
Mar 11, 2021

$17.92 (+6.86%)

Earnings
Q3 2020 Spero Therapeutics Inc Earnings Call Transcript
Nov 05, 2020

$13.89 (+0.14%)

Earnings
Spero Therapeutics Inc to Host a Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections Transcript
Sep 30, 2020
Q2 2020 Spero Therapeutics Inc Earnings Call Transcript
Aug 06, 2020

$12.69 (-3.35%)

Earnings
Spero Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference Transcript
May 13, 2020
Q1 2020 Spero Therapeutics Inc Earnings Call Transcript
May 08, 2020

$11.78 (-3.28%)

Earnings
Spero Therapeutics Inc at Cowen HealthCare Conference Transcript
Mar 02, 2020
Spero Therapeutics Inc KOL Breakfast Symposium: A Focus on the Spero Pipeline Transcript
Dec 05, 2019
Spero Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019

Q1 2022 Spero Therapeutics Inc Earnings Call Transcript

May 16, 2022 / 08:30PM GMT

Release Date Price: $1.71

Transcript 8-K10-Q

Operator

Good afternoon, and welcome to the Spero Therapeutics' First Quarter of 2022 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcements on the Spero Therapeutics' website at www.sperotherapeutics.com.

At this time, I would like to turn the conference over to Mr. Ted Jenkins, Vice President, Investor Relations at Spero Therapeutics. Mr. Jenkins, please go ahead.

Ted Jenkins

Spero Therapeutics, Inc. - VP & Head of IR

Thank you, operator, and thank you all for participating in today's conference call. This afternoon, Spero Therapeutics released financial results and provided a pipeline update for the first quarter of 2022. Our press release is available on the Investor page of Spero Therapeutics' website.

Before we begin, I'd like to remind you that some of the information contained in the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.